Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • Biotech
  • FDA
  • General
  • News

Aurinia Pharma Offers Updated Interim Results From AURORA 2 Continuation Study Of LUPYNIS For Treatment Of Lupus Nephritis

By Benzinga Newsdesk
Today, 10:43 PM
- Longest available outcomes data with LUPKYNIS will be presented virtually during American College of Rheumatology (ACR) Convergence 2021; final results expected by the end of 2021 – - Updated interim analysis

AUPH

Read More
7 minute read
  • Analyst Ratings
  • Downgrades
  • Initiation
  • Intraday Update
  • Upgrades

Benzinga’s Top Ratings Upgrades, Downgrades For October 28, 2021

By Benzinga Insights
Today, 10:43 PM
 

AGNC

Read More
1 minute read
  • Analyst Ratings
  • Downgrades
  • News
  • Price Target

Oppenheimer Downgrades Aurinia Pharmaceuticals to Perform, Raises Price Target to $32

By Benzinga Newsdesk
Today, 10:43 PM
Oppenheimer analyst Justin Kim downgrades Aurinia Pharmaceuticals (NASDAQ:AUPH) from Outperform to Perform and raises the price target from $28 to $32.

AUPH

Read More
2 minute read
  • Long Ideas
  • News
  • Short Ideas
  • Small Cap
  • Trading Ideas

Trump’s SPAC Partner Emerges As Top WallStreetBets Interest; Facebook, Snapchat, Tesla And These Are Other Top Trends

By Madhukumar Warrier
Today, 10:43 PM
Heading into a new trading week, Digital World Acquisition Corp. (NASDAQ: DWAC) has emerged as the most-discussed stock on Reddit’s r/WallStreetBets forum, while Facebook Inc.

AMZN

Read More
5 minute read
  • Markets
  • Movers
  • News
  • Penny Stocks
  • Pre-Market Outlook
  • Small Cap
  • Trading Ideas

55 Biggest Movers From Friday

By Lisa Levin
Today, 10:43 PM
Gainers

AGEN

Read More
6 minute read
  • Biotech
  • FDA
  • General
  • Guidance
  • Legal
  • News
  • Offerings
  • Penny Stocks
  • Small Cap

The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs

By Shanthi Rexaline
Today, 10:43 PM
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20)

ABEO

Read More
7 minute read
  • Biotech
  • FDA
  • General
  • IPOs
  • News
  • Offerings
  • Penny Stocks
  • Small Cap

The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs

By Shanthi Rexaline
Today, 10:43 PM
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14)

ACAD

Read More
6 minute read
  • Biotech
  • FDA
  • General
  • M&A
  • News
  • Penny Stocks
  • Small Cap

The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen’s Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout

By Shanthi Rexaline
Today, 10:43 PM
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13)

ABT

Read More
3 minute read
  • M&A

Aurinia Pharma Shares Up 3.7% Following Earlier Press Release From Co. Disclosing It Entered Deal To Be Acquired By Unnamed ‘Pharma Behemoth’ At $35+/ADS

By Benzinga Newsdesk
Today, 10:43 PM
Aurinia Pharmaceuticals (NASDAQ:AUPH) (the “Company”) is pleased to announce that it will enter into a definitive agreement with a pharma behemoth. The leading pharmaceutical company is in talks with AUPH for

AUPH

Read More
1 minute read
  • Asset Sales
  • Biotech
  • General
  • Health Care
  • M&A
  • News
  • Small Cap

Aurinia Adds Two Assets To Expand Its Immunology Pipeline

By Vandana Singh
Today, 10:43 PM
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has added two assets to expand its rare autoimmune and kidney-related disease pipeline. The first program, AUR200,…

AUPH

Posts navigation

Previous 1 … 6 7 8 … 10 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service